ArticleFibrogenesis & tissue repair2010
Achievements and challenges in bioartificial kidney development.
Article in Fibrogenesis & tissue repair, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 45 citations in OpenAlex.
- A human in vitro model that mimics the renal proximal tubule.Tissue engineering. Part C, Methods · 2014Trial
- Research Progress and Critical Challenges of Bioartificial Kidneys in Renal Replacement Therapy for End-Stage Renal Disease.Biomolecules · 2026Review
- Artificial kidney: Challenges and opportunities.World journal of transplantation · 2024Review
- High-throughput "read-on-ski" automated imaging and label-free detection system for toxicity screening of compounds using personalised human kidney organoids.Journal of Zhejiang University. Science. B · 2022Article
- Urine-derived cells for human cell therapy.Stem cell research & therapy · 2018Review
- Bioartificial Kidneys.Current stem cell reports · 2017Article
- Novel surgical techniques, regenerative medicine, tissue engineering and innovative immunosuppression in kidney transplantation.Archives of medical science : AMS · 2016Article
- Bioengineered kidney tubules efficiently excrete uremic toxins.Scientific reports · 2016Article
- Stem Cells and Regenerative Medicine: Myth or Reality of the 21th Century.Stem cells international · 2015Review
- Is regenerative medicine a new hope for kidney replacement?Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2014Review
- Regeneration and bioengineering of the kidney: current status and future challenges.Current urology reports · 2014Review
- Evaluation of bioartificial renal tubule device prepared with human renal proximal tubular epithelial cells cultured in serum-free medium.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2013Article
- A novel design of bioartificial kidneys with improved cell performance and haemocompatibility.Journal of cellular and molecular medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bioartificial kidneys (BAKs) combine a conventional hemofilter in series with a bioreactor unit containing renal epithelial cells. The epithelial cells derived from the renal tubule should provide transport, metabolic, endocrinologic and immunomodulatory functions. Currently, primary human renal proximal tubule cells are most relevant for clinical applications. However, the use of human primary cells is associated with many obstacles, and the development of alternatives and an unlimited cell source is one of the most urgent challenges. BAKs have been applied in Phase I/II and Phase II clinical trials for the treatment of critically ill patients with acute renal failure. Significant effects on cytokine concentrations and long-term survival were observed. A subsequent Phase IIb clinical trial was discontinued after an interim analysis, and these results showed that further intense research on BAK-based therapies for acute renal failure was required. Development of BAK-based therapies for the treatment of patients suffering from end-stage renal disease is even more challenging, and related problems and research approaches are discussed herein, along with the development of mobile, portable, wearable and implantable devices.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.